Form 4: Spyre Therapeutics Director Jeffrey W. Albers Sells 6,700 Shares Under 10b5-1 Plan

Director Jeffrey W. Albers sold 6,700 shares of Spyre Therapeutics (SYRE) common stock at an average price of $36.7631, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 6, 2024, Jeffrey W. Albers, a director of Spyre Therapeutics, Inc. (SYRE), sold 6,700 shares of common stock.
• The sale was executed at a price of $36.7631 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on April 16, 2024.
• Following the transaction, Albers directly owns 27,360 shares indirectly through Sessions LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales by company directors are a normal part of corporate governance. Investors often look to the reasons behind these sales, especially if they are not pre-planned, for signals about the company's prospects. In this case, the sale was pre-planned under a 10b5-1 plan, which is often seen as less indicative of the director's view of the company's future.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate insiders to sell shares while avoiding accusations of insider trading.
• The volume of shares sold (6,700) is relatively small compared to the total outstanding shares of Spyre Therapeutics, suggesting it is unlikely to have a significant impact on the stock price.
• Comparable companies in the biotechnology sector often see similar insider transactions as part of executives' compensation and financial planning.

Stakeholder Impact

• The sale of shares by a director could have a minor psychological impact on shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates